Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: Attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Constance, Christian ^a   Ben Yehuda, Ori ^b   Wenger, Nanette K ^c   Zieve, Franklin ^d   Lin, Jianxin ^e   Hanson, Mary E ^e   Lowe, Robert S ^e   Tershakovec, Andrew M ^e  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; Combination therapy; Elderly; Ezetimibe; Hyperlipidemia; Statin

Indexed keywords

AGED; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CANADA; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MULTICENTER STUDIES AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84892425986     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-13     Document Type: Article

References (18)

1. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M, European Cardiovascular Disease Statistics 2012 Brussels, Belgium: European Heart Network AISBL & European Society of Cardiology, Løgstrup S, O'Kelly S, 2012 & Sophia Antipolis, France
2. Mortality, Summary List of Causes 2009 Ottowa, Canada: Health Statistic Division, Statistics Canada 2012
3. - 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E, Can J Cardiol 2013 29 151 167 10.1016/j.cjca.2012.11.032 23351925
4. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholteop Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, Eur Heart J 2012 33 1635 1701 22555213
5. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E, J Am Coll Cardiol 2006 48 438 445 10.1016/j.jacc.2006.04.070 16875966 (Pubitemid 44109954)
6. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the study assessing goals in the elderly (SAGE). Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D, Circulation 2007 115 700 707 10.1161/CIRCULATIONAHA.106.654756 17283260 (Pubitemid 46294760)
7. Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, J Am Coll Cardiol 2004 44 720 732 10.1016/j.jacc.2004.07.001 15358046
8. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Lancet 2002 360 1623 1630 10.1016/S0140-6736(02)11600-X 12457784 (Pubitemid 35379733)
9. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Zieve F, Wenger NK, Ben Yehuda O, Constance C, Bird S, Lee R, Hanson ME, Jones-Burton C, Tershakovec AM, Am J Cardiol 2010 105 656 663 10.1016/j.amjcard.2009.10.029 20185012
10. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Circulation 2002 106 3143 3421 12485966
11. Joint British societies' guidelines on prevention of cardiovascular disease in clinical practice. JBS 2, Heart 2005 91 Suppl 5 &221 v52 16365341
12. The comparative efficacy of ezetimibe added to atorvastatin 10 mg versus uptitration to atorvastatin 40 mg in subgroups of patients aged 65 to 74 years or greater than or equal to 75 years. Ben Yehuda O, Wenger NK, Constance C, Zieve F, Hanson ME, Lin JX, Shah AK, Jones-Burton C, Tershakovec AM, J Geriatr Cardiol 2011 8 1 11 10.3724/SP.J.1263.2011.00001 22783278
13. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, Da Silva PM, Pedersen T, Wood D, Junger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ, Eur J Prev Cardiol 2012 19 221 230 10.1177/1741826711400545 21450578
14. Implications of statin adverse effects in the elderly. Golomb BA, Expert Opin Drug Saf 2005 4 389 397 10.1517/14740338.4.3.389 15934847 (Pubitemid 40723714)
15. AstraZeneca, Crestor (rosuvastatin calcium) tablets [package insert] Wilmington, DE, AstraZeneca: USA 227 2011
16. Merck & Co I, Zocor (simvastatin) tablets [package insert] Whitehouse Station, NJ, Merck & Co Inc: USA 2011
17. Novartis, Lescol (fluvastatin sodium) capsules [package insert] East Hanover, NJ, Novartis: USA 2011
18. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. Robinson JG, Davidson M, Shah A, Lin J, Neff D, DeLucca P, Tomassini JE, Veltri E, Tershakovec AM, Aging Health 2007 3 691 705 10.2217/1745509X.3.6.691